Third Rejection: What a Final Office Action Really Means

The final office action lands in your inbox. Third rejection. Months of work and real budget already spent.

For many founders, this feels like the end of the road. It isn't. In strategic prosecution, a final rejection is a decision point, not a verdict. Here's how to play it to win.

You have three live paths: appeal to the PTAB, file an RCE, or file a continuation. The skill is matching the tool to your situation.

The USPTO raised second-and-subsequent RCE fees sharply in 2025. Stack a second RCE against a fresh continuation, and the continuation is now cheaper at every entity tier:

• Large: $2,000 vs. $2,860

• Small: $800 vs. $1,144

• Micro: $400 vs. $572

What that means for strategy

The old reflex of stacking RCE on RCE in the same application is now the more expensive path, not the cheaper one.

Your options after a final rejection

1. First RCE

Best ROI when the examiner has shown you the finish line. If an interview gave you a concrete "Claim 1 is allowable if you add X," pay the fee ($300 micro, $600 small) and close it out. Cheap, fast, done.

2. Continuation

Best ROI when one RCE hasn't resolved it. It costs less than a second RCE and, more importantly, gives you a true reset: out from under the final rejection, a fresh first action on the merits, and full claim flexibility without RCE-loop baggage.

One caveat worth mentioning: a continuation usually keeps the same examiner, so this is a reset on your claims and posture, not a new decision-maker.

3. Appeal

The right call when the disagreement is legal, not a claim-language fix, and you genuinely need a different decision-maker. The PTAB, not a continuation, is how you actually escape an examiner.

How to win

Run the split strategy. Take narrow claims to allowance now for immediate protection, while a continuation pursues the broader coverage your spec supports. You get an issued asset on the board and keep your upside alive.

Think in portfolios, not single patents. Multiple applications from one disclosure broaden the IP moat around your technology.

The winning question isn't "Can we overcome this rejection?" It's "Which path builds the most portfolio value given our budget and where the business is headed?"